Dendreon Corp (OTC Pink - Limited Information:DNDNQ)

0.0305
Delayed Data
As of 3:59pm ET
 -0.0015 / -4.69%
Today’s Change
0.03
Today|||52-Week Range
2.49
-58.22%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$5.1M

Company Description

Dendreon Corp. is a biotechnology company, which focuses on discovery, development and commercialization of novel therapeutics that improves cancer treatment options for patients. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA.

Contact Information

Dendreon Corp.
1301 2nd Avenue
Seattle Washington 98101
P:(206) 256-4545
Investor Relations:

Employees

Shareholders

Individual stakeholders5.19%
Mutual fund holders1.41%
Other institutional0.18%

Top Executives

Robert L. CrottyPresident, Secretary & General Counsel
Gregory R. CoxChief Financial Officer & Treasurer
William MonteithExecutive Vice President-Technical Operations
Andrew S. SandlerChief Medical Officer & Executive Vice President
Karen BrophyVice President & Head-Human Resources

To view my watchlist

Not a member yet?

Sign up now for a free account